Valuation Watch: Anti-Infectives a Rare Bright Spot for Last Crop of Biotech IPOs
This article was originally published in Start Up
Executive Summary
Most of the 15 biotech IPOs in the US in 2007 have performed poorly on the public markets. There have been exceptions: Sirtris was acquired by GSK at a significant premium to its IPO price. And anti-infectives focused biotechs Pharmasset and Optimer have outclassed their peers as they have outperformed the market.